Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Revenue (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Revenue for 6 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue rose 75.73% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.3 million, a 18.76% increase, with the full-year FY2024 number at $15.0 million, up 8.91% from a year prior.
  • Revenue was $6.8 million for Q3 2025 at Vivos Therapeutics, up from $3.8 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $6.8 million in Q3 2025 to a low of $3.0 million in Q1 2025.
  • A 5-year average of $4.0 million and a median of $3.9 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: dropped 22.26% in 2023, then surged 75.73% in 2025.
  • Vivos Therapeutics' Revenue stood at $4.4 million in 2021, then fell by 10.11% to $4.0 million in 2022, then dropped by 17.77% to $3.2 million in 2023, then rose by 13.85% to $3.7 million in 2024, then surged by 83.42% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Revenue are $6.8 million (Q3 2025), $3.8 million (Q2 2025), and $3.0 million (Q1 2025).